 |
|
|
|
PROCYTE PRODUCTS - FROM HOLLYWOOD TO THE HAMPTONS
Redmond, Wash.—July 26, 2004—ProCyte Corporation (OTCBB: PRCY.OB),
a company that markets skin care and
procedure related products in the dermatology, cosmetic surgery and spa
markets based on its patented Copper Peptide technologies, today
announced that its Neova® Therapy skin care products are
making the rounds in Hollywood.
At the July 3rd wedding of
Tori Spelling, personalized Neova® product gift baskets were
presented to the bridal wedding party. Groomsmen received products
including Neova® After Shave Therapy with GHK Copper Peptide
Complex® technology. The wedding and products are
tentatively scheduled to appear in the InStyle Wedding Issue in
early 2005.
Dr. Barbara
Schell, noted Seattle cosmetic surgeon and dermatologist, commented “The
GHK Copper Peptide technology has been shown to help decrease the
appearance of fine lines and wrinkles while evening out skin tone. This
makes it ideal for daily use and minimizes any concerns that skin
irritation will interfere with a special occasion.”
Not to be left
out, the contestants of the highly popular The Bachelor series
each received ProCyte anti-aging product kits. Eight lucky viewers will
win their own Neova® product kits. More information can be
found on The Bachelor website beginning with the new season in
September.
Hamptons
Magazine July issue features
ProCyte’s Ti-Tan™ Self-Tanner to help keep
a golden glow without sun exposure. The product is a popular companion
product to ProCyte’s Ti-Silc® sunblock – a leading high
performance sun protection product recommended by dermatologists.
Soap Opera Digest August 2nd issue highlights Tamara
Braun (Carly from daytime series General Hospital), who raves
about Ti-Silc® sunblock.
ProCyte products
are sold by leading dermatologists and plastic surgeons and through the
Internet via physician-related websites such as
www.dermadoctor.com,
www.agelessinseattle.com, and
www.skincarerx.com as well as others.
ProCyte
Corporation develops and markets products based on its patented,
clinically proven Copper Peptide technology for skin health, hair care
and wound care. The Company sells directly to dermatologists, plastic
and cosmetic surgeons, spas and salons and through licenses with
strategic partners into the consumer market, including its long-term
worldwide license agreement with Neutrogena®, a Johnson &
Johnson company. ProCyte brands include Neova ®,
VitalCopper™,
Simple Solutions®
and AquaSanté®
Skin Care products; Complex Cu3®
Post-Procedure Skin Care; GraftCyte®
Hair Transplant Care; and Tricomin®
Advanced Care for Thinning Hair. The Company also has the exclusive
distribution rights for Cutanix Corporation’s Quadrinone®
technology in the U.S., Canada and Puerto Rico. Additional information
is available by visiting the Company’s website at www.procyte.com.
###
This release may contain forward-looking statements relating to the
research, development, commercialization, production, marketing and
distribution of the Company's products and future operating results,
which are subject to certain risks and uncertainties that could cause
actual results to differ materially from those projected.
The
words “believe,” “expect,” “intend,” “anticipate,” variations of such
words, and similar expressions
identify forward-looking statements, but their absence does not mean
that the statement is not forward-looking. These statements are not
guarantees of future performance and are subject to certain risks,
uncertainties and assumptions that are difficult to predict. Factors
that could affect the Company’s actual results include its ability to
develop, commercialize and produce new products; the market acceptance
of existing and potential future products; the availability, cost and
timely delivery of materials and services from and performance of
third-party suppliers, manufacturers, distributors, licensees and other
collaborative partners; the satisfaction of regulatory requirements, and
the receipt, timing, terms and conditions of required regulatory
approvals. Reference is made to the Company’s Annual Report on Form
10-K for the year ended December 31, 2003 and its latest quarterly
report on Form 10Q filed with the Securities and Exchange Commission for
a more detailed description of such factors. Readers are cautioned not
to place undue reliance on these forward-looking statements, which speak
only as of the date of this release. The Company undertakes no
obligation to publicly update any forward-looking statement to reflect
new information, events or circumstances after the date of this release
or to reflect the occurrence of unanticipated events.
|
|
|
|
